ArticleBMC cardiovascular disorders2025
The effect of high-fat diet on serum metabolites in rats with heart failure: a non-targeted metabolomics approach.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to explore the potential mechanism underlying the effects of a high-fat diet (HFD) on heart failure (HF), utilizing the integration of serum metabolomics.
methodA Sprague-Dawley rat model for HF induced by pressure overload via abdominal aortic contraction was established. A metabolomics approach based on liquid chromatography-mass spectrometry (LC-MS) was performed to analyze the serum biomarkers from control + chew diet (CCD) group, model + chew diet (MCD) group, and model + HFD(MHFD) group. Principal component analysis (PCA) and orthogonal projection to latent structures-discriminan* t analysis (OPLS-DA) were employed to identify differences in metabolic profiles among the three groups.
resultsThere were significant differences in OPLS-DA scores between the CCD vs. MCD groups and MCD vs. MHFD groups. In comparison to the CCD group, the MCD group demonstrated significant alterations in multiple metabolites, such as Lyso PE (20:4 (5Z, 8Z, 11Z, 14Z))/0:0, Lyso PE (16:0/0:0), L-glutamine, N2-γ-glutamine, butyrylcarnitine, PHOOA-P, and so on. In addition, the levels of metabolites such as cholic acid, (9 S, 10E, 12 S, 13 S) -9,12,13-trihydroxyoctadec-10-enoylcarnitine, and 8-deoxy19,20-epoxycytidine C in the MHFD group were significantly higher than those in the MCD group. 17 metabolites showed a significant restorative trend from HF to a normal condition, implying their significant relationship with the positive effects of HFD on HF. These metabolites can be considered potential biomarkers for HFD treatment.
conclusionsThese results can be used to better understand the effects of HFD on HF rats, which will provide new ideas for treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.